What Expedition Medicines does

Expedition Medicines is a privately held biotechnology company founded in 2022 by Flagship Pioneering and based in Cambridge, Massachusetts. The company operates in the drug discovery stage of biopharmaceutical development, building a generative AI platform that combines quantum covalent chemistry, chemoproteomics, and machine learning to design small molecule drugs against protein targets historically considered undruggable. Its core scientific insight, termed "Reaction First" covalent chemistry, identifies latent catalytic sites on protein surfaces that can catalyze covalent bond formation, enabling targeting of proteins lacking traditional deep binding pockets such as transcription factors, adaptor proteins, and protein-protein interaction interfaces. The platform is underpinned by a chemoproteomics data generation engine that measures molecular potency across 20,000+ proteomic sites at amino acid resolution, producing what the company describes as the richest dataset in covalent drug discovery.

The company's discovery pipeline spans oncology (including bifunctional degraders and PPI inhibitors) and immunology/allergy (allosteric inhibitors), with a multi-target exploration agreement with Pfizer focused on prostate cancer. Expedition is pre-revenue and operates a B2B partnership-driven business model, generating future value through licensing agreements, milestone payments, and royalties with pharmaceutical partners. The company employs 11-50 people, led by CEO Molly Gibson (formerly of Lila Sciences and Generate Biomedicines), with senior leadership drawn from Vividion Therapeutics, Atomwise, and other category-defining biotech and AI companies. Flagship Pioneering provided an initial $50 million commitment upon the company's emergence from stealth in October 2025, following three years of internal platform development.

Name

Expedition Medicines

Legal name

Expedition Medicines, Inc.

Website

https://expeditionmedicines.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Expedition Medicines is a Cambridge-based biotech using generative AI, quantum chemistry, and chemoproteomics to design covalent small molecule drugs against previously undruggable proteins, partnering with pharmaceutical companies like Pfizer to advance programs in oncology and immunology.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Discovery & Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• Generative AI drug discovery
• Covalent small molecule therapeutics
• Chemoproteomics screening platform
• Undruggable protein targets
• Quantum chemistry drug design

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing and Development Partnerships: As a pre-revenue biotech company, Expedition Medicines generates value through licensing agreements and co-development partnerships with pharmaceutical companies. The company develops drug candidates through preclinical and clinical stages, with partners like Pfizer, and may receive milestone payments and royalties on approved products.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Expedition Medicines develops a generative AI platform that combines quantum chemistry, chemoproteomics, and machine learning to design covalent small molecule drugs against previously undruggable disease-driving proteins. The platform is supported by a continuous chemoproteomics data generation engine that measures molecular potency across the entire proteome at amino acid resolution, producing what the company describes as the richest dataset in covalent drug discovery. The company monetizes these capabilities through pharmaceutical licensing and co-development partnerships, with an active multi-target exploration agreement with Pfizer focused on prostate cancer and discovery programs in oncology and immunology/allergy.

Product overview

Expedition Medicines operates as a platform company built around two interconnected core offerings: its Quantum Chemistry AI Platform and the Chemoproteomics Data Generation Engine. The chemoproteomics engine serves as the data generation backbone, running 24/7 to measure molecular potency across the proteome at amino acid resolution, creating a proprietary dataset that fuels the AI platform. The AI platform then uses this data to generatively design covalent small molecule drugs targeting previously undruggable proteins. Discovery programs span oncology (including a Pfizer collaboration for prostate cancer), immunology, and other diseases, with pipeline candidates including bifunctional degradaders, PPI inhibitors, and allosteric inhibitors at various stages.

Differentiator

Problem solved

Functional benefit

Products and services

• Quantum Chemistry AI Platform Generative AI platform combining quantum chemistry, chemoproteomics, and machine learning that learns rules of covalent bond formation at the electron level to design small molecule drugs against previously undruggable protein targets. The platform is used by Expedition Medicines to advance drug candidates in oncology, immunology, and other disease areas, and underpins its pharmaceutical partnerships.
• Chemoproteomics Data Generation Engine Industry-leading chemoproteomics screening and data generation engine that measures the potency of each molecule against the entire proteome at amino acid resolution (covering approximately 20,000 proteomic sites via mass spectrometry), running continuously to produce the proprietary dataset used to train Expedition's generative chemistry models.
• Pfizer Prostate Cancer Multi-Target Exploration Collaboration Strategic co-development collaboration under which Expedition Medicines uses its covalent discovery platform to identify small molecule candidates against previously undruggable protein targets with known correlation to prostate cancer disease progression and treatment resistance, with Pfizer as the development and commercialization partner.

Quantifiable outcome

• 80% of proteins linked to disease have no existing medicines targeting them
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

One partnership is on record.

• PfizercoreStrategic or Co-development Partner · 1 January 2023Multi-target exploration agreement to identify novel therapeutic candidates for prostate cancer. The collaboration was brokered by Flagship Pioneering in 2023 as part of its Pioneering Medicines Initiative with Pfizer. The research aims to identify molecules targeting previously undruggable proteins with known correlation to prostate cancer disease progression and treatment resistance. The agreement is subject to terms of the 2023 Flagship-Pfizer partnership.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Recursion Pharmaceuticals: Public AI-driven drug discovery platform combining high-throughput biology with ML; comparable as a larger, better-capitalized AI biotech competitor pursuing multiple therapeutic programs.
• Isomorphic Labs: Alphabet-backed AI drug discovery company using deep learning for structure-based design; broadly comparable as a well-capitalized AI-pharma platform pursuing novel small molecule discovery.
• Schrödinger, Inc. Computational chemistry platform combining physics-based modeling with ML for small molecule discovery; comparable as a more mature, publicly listed computational drug discovery peer with multiple pharma collaborations.
• Insitro: ML-driven drug discovery combining high-throughput biology and predictive models; comparable as a venture-backed AI biotech with pharma partnerships across multiple disease areas.

Direct peers

• Generate:Biomedicines: Generative AI platform for protein-based drug design; Flagship Pioneering sister company. Directly comparable as a Flagship-originated generative-AI biotech with overlapping leadership (CEO Molly Gibson co-founded both).
• Lila Sciences: Flagship Pioneering AI Science Factory pursuing autonomous scientific experimentation across chemistry and biology; comparable as a sister Flagship company building AI-driven discovery infrastructure, with overlapping founders (CEO Molly Gibson co-founded Lila).
• Vividion Therapeutics: Pioneer in covalent drug discovery against traditionally undruggable targets using chemoproteomics; acquired by Bristol Myers Squibb. Highly comparable in scientific approach (covalent chemistry + chemoproteomics), and Expedition's CSO and CSO of Drug Discovery are Vividion alumni.
• Atomwise: AI-driven small molecule drug discovery using deep learning; comparable in applying ML to hit identification and lead optimization, and Expedition's CTO Henry van den Bedem was Atomwise's SVP of ML Research.

Emerging players

• BenevolentAI: AI-driven drug discovery company applying ML to biomedical knowledge graphs and target identification; comparable as a public AI biotech with partnerships across pharma.
• HotSpot Therapeutics: Discovery platform focused on identifying allosteric and regulatory sites on proteins for small molecule drug discovery; comparable for its focus on 'undruggable' targets via non-traditional binding mechanisms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/expedition-medicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Expedition Medicines